Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
46.53
+0.12 (0.26%)
Nov 20, 2026, 4:00 PM EST - Market closed
Enliven Therapeutics Employees
Enliven Therapeutics had 65 employees as of September 30, 2026. The number of employees did not change compared to the same quarter last year. That makes Enliven Therapeutics the 33,854th largest employer in the world and 4,428th in the United States.
Employees
65
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,745,877
Market Cap
3.42B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 65 | 0 | - |
| Jun 30, 2026 | 67 | 4 | 6.35% |
| Mar 31, 2026 | 61 | -4 | -6.15% |
| Dec 31, 2025 | 60 | -2 | -3.23% |
| Sep 30, 2025 | 65 | 8 | 14.04% |
| Jun 30, 2025 | 63 | 11 | 21.15% |
| Mar 31, 2025 | 65 | 15 | 30.00% |
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Sep 30, 2024 | 57 | 13 | 29.55% |
| Jun 30, 2024 | 52 | 15 | 40.54% |
| Mar 31, 2024 | 50 | 21 | 72.41% |
| Dec 31, 2023 | 46 | 17 | 58.62% |
| Sep 30, 2023 | 44 | 20 | 83.33% |
| Jun 30, 2023 | 37 | 13 | 54.17% |
| Mar 31, 2023 | 29 | - | - |
| Sep 30, 2022 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 3,300 |
| Iovance Biotherapeutics | 975 |
| AbCellera Biologics | 562 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Viridian Therapeutics | 252 |
| Relay Therapeutics | 218 |
ELVN News
- 4 days ago - Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 15 days ago - Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update - PRNewsWire
- 15 days ago - Enliven Therapeutics Earnings release: Q3 2026 - Filings
- 15 days ago - Enliven Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Enliven price target raised to $73 from $65 at H.C. Wainwright - TheFly
- 5 weeks ago - Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year - PRNewsWire
- 6 weeks ago - Enliven reaches alignment with FDA on final design of ENABLE-2 pivotal trial - TheFly
- 6 weeks ago - Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia - PRNewsWire